A radical new cancer treatment is to be tested using cells from cancer survivors

In In The News by Barbara Jacoby

From: dailymail.co.uk

A radical new cancer treatment inspired by patients who seem to ‘shrug off’ the disease could be tested next year.

The technique uses potent cancer-killing cells from people with the strongest immune systems.

These ‘neutrophil’ cells – which form part of the body’s first line of defence – are then multiplied millions of times and injected into cancer patients.

They are believed to be a key reason why rare individuals spontaneously reject lethal cancers and seem to have ‘miracle recoveries’.

Following experiments with mice, a British company is now preparing for early trials of the neutrophil treatment on a small number of patients.

Alex Blyth, chief executive of Lift BioSciences, said: ‘We’re not talking about simply managing cancer. We’re looking at a curative therapy that you would receive once a week over the course of five to six weeks.

‘Based on our laboratory and mouse model experiments we would hope to see patients experiencing complete remission. Our ultimate aim is to create the world’s first cell bank of powerful cancer-killing neutrophils.’

The team – along with researchers from King’s College London – is initially focusing on pancreatic cancer, which is among the most lethal forms.

Each year around 9,618 people in the UK are diagnosed with pancreatic cancer and 8,817 die from the disease – which has a five-year survival rate of less than 3 per cent.

Early laboratory tests have also shown that neutrophils can kill cervical cancer cells.

Mr Blyth said key advantage of neutrophils is that a donor’s cells can be given to anyone without fear of serious rejection.

They live in the body for only five days and disappear before the recipient’s immune system has a chance to respond.

Neutrophils kill cancer cells either directly, by destroying them with chemicals and antibodies, or indirectly by recruiting other immune cells.

There is evidence that neutrophils may sometimes not recognise cancer as ‘foreign’ and can even shield tumours from other immune responses.

But when they do target cancer, they are highly efficient – wiping out 95 per cent of test cancer cells in 24 hours. It is neutrophils with this ability that form the basis of the new therapy.

The Lift team has collected thousands of the cells discarded as a waste product by blood banks, and is mass-screening them for their cancer-killing potential in a laboratory.

Those that pass the test are cultured and multiplied many times over using a secret process. The researchers are also working on a way of altering them to become even more potent.

Professor Farzin Farzaneh, who is leading the research at King’s College, said: ‘I was initially sceptical when Lift BioSciences approached us. It is something I don’t believe has been done before, and producing these specific cells with cancer-killing ability is a notion we had not thought of. We are excited by the early results.’

The pilot trials, potentially starting in a year’s time, would involve a small group of 20 to 40 patients with pancreatic cancer, or possibly a rare form of soft tissue cancer.

Each participant would receive weekly infusions of potent neutrophils. One patient’s treatment would require around 2.5billion of the cells.

So far Lift BioSciences has received no government money and raised around £250,000 for early research from drug giants Merck, MedCity which provides support for life sciences, and crowdfunding.

Diana Jupp, chief executive of Pancreatic Cancer UK, said: ‘There are very few treatment options for pancreatic cancer, a disease which 93 per cent of patients do not survive for five years.

‘Immunotherapy is a very promising area for pancreatic cancer research, and one that we are funding as a charity.

‘We know that pancreatic cancer puts up a barrier against immunotherapies, which makes it very difficult for them to reach pancreatic cancer cells and work as an effective treatment.

‘It will be very interesting to see the results of this trial, and understand more about how well the treatment breaks down this barrier and how effectively this could work as a treatment for pancreatic cancer in the future.’